Greenland Mines Ltd. (GRML) Stock Score, Valuation & Financial Research

Greenland Mines Ltd. is in the Basic Materials sector and Other Precious Metals industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GRML

Greenland Mines Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 5.82. These figures are a research snapshot, not a buy or sell recommendation.

What Greenland Mines Ltd. does

Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Greenland Mines Ltd. operates through two primary divisions: a mining division focused on the exploration and development of the Skaergaard Project in Greenland for palladium, gold, and platinum, and a biotechnology division that develops medicines for chronic diseases including cancer and neurodegenerative disorders.

Products and services

  • The company's portfolio includes the development of bio-generic antibodies for chronic disease treatment and the exploration of precious metal mineral deposits at the Skaergaard Project.

Customer types

Healthcare and pharmaceutical providers.

Business relationships and partnerships

  • Reliance Life Sciences — The company acquired two off-patent bio-generic antibodies from Reliance Life Sciences, the life science arm of Reliance Industries Pvt LTD. Source

Business strengths to evaluate

  • Ownership of a significant palladium, gold, and platinum deposit at the Skaergaard Project Source

Business risks and research considerations

  • Operational and development risks associated with mining exploration and biotechnology drug development Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GRML financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 5.82
Market capitalization:
17.51M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -21.77M
Free cash flow:
USD -5.86M
Cash:
USD 9.34M
Total debt:
USD 297.97K
EPS:
USD -12.29

What stands out

  • Free cash flow is USD -5.86M, negative for the stored period.
  • The balance sheet shows USD 9.34M of cash versus USD 297.97K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 9.05M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GRML

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can GRML fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is GRML likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for GRML to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of GRML's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research GRML

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.